Edward P Acosta Selected Research

Raltegravir Potassium

3/2021	Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis.
1/2020	Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110).
12/2019	Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110.
11/2019	Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis.
11/2014	Raltegravir pharmacokinetics in neonates following maternal dosing.
1/2013	Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics.
11/2012	Measurement of plasma and intracellular concentrations of raltegravir in patients with HIV infection.
2/2012	Acceptable plasma concentrations of raltegravir and etravirine when administered by gastrostomy tube in a patient with advanced multidrug-resistant human immunodeficiency virus infection.
1/2012	A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Edward P Acosta Research Topics

Disease

27	Acquired Immunodeficiency Syndrome (AIDS) 01/2022 - 07/2002
16	Infections 04/2020 - 04/2004
14	HIV Infections (HIV Infection) 01/2020 - 08/2002
7	Viremia 01/2021 - 05/2008
4	Neoplasms (Cancer) 01/2022 - 12/2009
3	Cystic Fibrosis (Mucoviscidosis) 01/2022 - 01/2018
2	Tuberculosis (Tuberculoses) 03/2021 - 11/2019
2	Prostatic Neoplasms (Prostate Cancer) 01/2020 - 03/2017
2	Inflammation (Inflammations) 01/2018 - 09/2014
2	Exanthema (Rash) 12/2015 - 02/2014
2	Human Influenza (Influenza) 03/2013 - 08/2010
2	Hypertriglyceridemia 04/2008 - 12/2003
1	Lymphoma (Lymphomas) 01/2022
1	Triple Negative Breast Neoplasms 01/2021
1	COVID-19 01/2021
1	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2019
1	Hematologic Neoplasms (Hematological Malignancy) 01/2019
1	Soft Tissue Infections 01/2017
1	Hypophysitis 01/2017
1	Thrombocytopenia (Thrombopenia) 01/2017
1	Sepsis (Septicemia) 03/2016
1	Myocarditis (Carditis) 03/2016
1	Hepatitis 03/2016
1	Chronic Bronchitis 01/2016
1	Immune Reconstitution Inflammatory Syndrome 12/2015
1	Ureaplasma Infections (Ureaplasma Infection) 03/2014
1	Psychomotor Agitation (Akathisia) 02/2014
1	Sleep Initiation and Maintenance Disorders (Insomnia) 02/2014
1	Esophagitis 02/2012
1	Esophageal Perforation 02/2012
1	Chronic Hepatitis B 02/2012

Drug/Important Bio-Agent (IBA)

12	Pharmaceutical PreparationsIBA 11/2019 - 08/2002
11	efavirenz (Sustiva)FDA Link 01/2019 - 04/2004
9	Raltegravir Potassium FDA Link 03/2021 - 01/2012
7	RNA (Ribonucleic Acid)IBA 01/2021 - 08/2006
7	Protease Inhibitors (Protease Inhibitor)IBA 01/2019 - 08/2002
7	Ritonavir (Norvir)FDA Link 01/2019 - 12/2003
6	Emtricitabine (Emtriva)FDA Link 01/2019 - 01/2012
6	Tenofovir (Viread)FDA Link 01/2019 - 01/2012
6	Reverse Transcriptase InhibitorsIBA 10/2012 - 08/2002
5	Lamivudine (Epivir)FDA Link 01/2019 - 07/2002
5	NucleosidesIBA 08/2006 - 07/2002
4	ivacaftorIBA 01/2022 - 01/2016
4	dolutegravirIBA 01/2022 - 01/2017
4	Nevirapine (Viramune)FDA Link 08/2013 - 02/2004
3	Rifampin (Rifampicin)FDA LinkGeneric 03/2021 - 09/2007
3	Maraviroc FDA Link 01/2019 - 01/2012
3	Cytochrome P-450 CYP2B6 (CYP2B6)IBA 08/2014 - 09/2010
3	Zidovudine (Retrovir)FDA LinkGeneric 08/2013 - 07/2002
3	Antiviral Agents (Antivirals)IBA 01/2011 - 01/2007
3	Indinavir (Crixivan)FDA Link 01/2008 - 10/2002
2	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 01/2018
2	Docetaxel (Taxotere)FDA Link 01/2020 - 03/2017
2	Azithromycin (Zithromax)FDA LinkGeneric 06/2015 - 03/2014
2	Lopinavir FDA Link 04/2014 - 08/2013
2	Transaminases (Aminotransferases)IBA 02/2014 - 03/2009
2	Oseltamivir (Tamiflu)FDA Link 03/2013 - 08/2010
2	Cytochrome P-450 CYP3AIBA 09/2010 - 09/2007
2	abacavir (Ziagen)FDA Link 08/2006 - 04/2004
2	Saquinavir (Invirase)FDA Link 11/2005 - 04/2004
2	Nelfinavir (Viracept)FDA Link 10/2005 - 04/2004
1	glucarpidaseIBA 01/2022
1	Methotrexate (Mexate)FDA LinkGeneric 01/2022
1	tezacaftorIBA 01/2022
1	Tacrolimus (Prograf)FDA LinkGeneric 01/2022
1	elexacaftorIBA 01/2022
1	ivacaftor drug combination tezacaftorIBA 01/2022
1	Positive Transcriptional Elongation Factor BIBA 01/2021
1	Biological ProductsIBA 01/2021
1	Lapatinib (GW572016)FDA Link 01/2021
1	Transcription Factors (Transcription Factor)IBA 01/2021
1	veliparibIBA 01/2021
1	Histones (Histone)IBA 01/2021
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2021
1	Human immunodeficiency virus 1 p31 integrase proteinIBA 01/2020
1	phytobacteriomycin (PBM)IBA 01/2020
1	mavorixaforIBA 01/2019
1	lamivudine drug combination abacavir FDA Link 01/2019
1	Atazanavir Sulfate (Reyataz)FDA Link 01/2019
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2018
1	Enfuvirtide (Fuzeon)FDA Link 10/2017
1	ResveratrolIBA 03/2017
1	BMS-936559IBA 01/2017
1	RacivirIBA 01/2017
1	pleconarilIBA 03/2016
1	CreatinineIBA 09/2015
1	MacrolidesIBA 06/2015
1	NeopterinIBA 09/2014
1	HIV IntegraseIBA 01/2013
1	Anti-Retroviral Agents (Antiretroviral Agents)IBA 01/2013
1	etravirine (TMC-125)FDA Link 02/2012
1	Darunavir (Prezista)FDA Link 01/2012

Therapy/Procedure

14	Therapeutics 01/2020 - 11/2005
6	Highly Active Antiretroviral Therapy (HAART) 01/2017 - 01/2004
2	Art Therapy 01/2018 - 05/2009
2	Drug Therapy (Chemotherapy) 02/2012 - 12/2009
1	Liver Transplantation 01/2022
1	Transplantation 01/2019
1	Cell Transplantation 01/2019
1	Gastrostomy 02/2012